At a Glance
- Acquirer: Teva Pharmaceuticals
- Target: Emalex Biosciences
- Deal value: $700M upfront + $200M milestones + royalties
- Asset: ecopipam (D1 antagonist)
- Next steps: NDA H2 2026
What happened?
Teva Pharmaceuticals announced on 29 April 2026 it will acquire Emalex Biosciences for $700 million upfront, with up to $200 million in commercial milestones and royalties. The deal adds ecopipam, an NDA-ready first-in-class dopamine D1 receptor antagonist for paediatric Tourette syndrome.
Why does it matter?
Ecopipam addresses unmet need in Tourette syndrome (TS), where current D2 antipsychotics cause side effects. Phase 3 data showed significant tic reduction (p=0.0084); Orphan/Fast Track designations. Teva’s neuroscience expertise (Austedo/Uzedy growth) positions it for launch success.
Who’s behind it?
Teva’s largest acquisition in a decade; Emalex’s ecopipam from prior development. CEO Richard Francis highlighted Pivot to Growth strategy alignment.
How was it achieved?
Positive Phase 3 met primary endpoint; NDA planned H2 2026. Funded by cash; closes Q3 2026 pending approvals.
What’s next?
NDA submission H2 2026; Teva builds paediatric sales force. Potential expansion beyond TS.
What are people saying?
Richard Francis, Teva CEO: “Expands innovative pipeline… leverages neuroscience strengths.” Eric Messner, Emalex CEO: “Teva’s scale will bring ecopipam to patients broadly.”